Gilead to Test Remdesivir Delivered Through Inhalation

July 3, 2020

Gilead to Test Remdesivir Delivered Through Inhalation

Gilead will begin testing an inhaled version of their leading COVID-19 treatment, Remdesivir. It is currently administered to patients intravenously in a hospital setting, though delivery via a nebulizer is decidedly more patient-centric. Regardless of dosage form, Yourway has the means to transport, store, and ship even the most sensitive clinical trial samples globally.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Schedule a Meeting

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Schedule a Meeting

Media

Articles

Keeping trials on track: Prioritizing communication in decentralized trials

Open chat

Hello! How can I help you?